InsiderTrades.com logo

James Huang Biography and Net Worth

Director of Connect Biopharma
  • Phone
  • Email
  • Website


Mr. Huang has over 30 years of biotech experience and he is the Founding Partner of Panacea Venture, an investment firm with its focus on innovative and transformative healthcare and life sciences companies worldwide. Mr. Huang served as managing partner at Kleiner Perkins (KPCB) China and Vivo Ventures, and he served in various leadership roles with Anesiva, Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Myers Squibb Company and ALZA Corp. He is currently a member of a number of private and public boards. Mr. Huang received an M.B.A. from Stanford and a B.S. degree in chemical engineering from University of California, Berkeley.

What is James Huang's net worth?

The estimated net worth of James Huang is at least $31.01 million as of May 29th, 2026. Mr. Huang owns 13,310,000 shares of Connect Biopharma stock worth more than $31,012,300 as of August 26th. This net worth evaluation does not reflect any other investments that Mr. Huang may own. Learn More about James Huang's net worth.

How do I contact James Huang?

The corporate mailing address for Mr. Huang and other Connect Biopharma executives is East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road, TAICANG F4, 215400. Connect Biopharma can also be reached via phone at 18587271045 and via email at [email protected]. Learn More on James Huang's contact information.

Has James Huang been buying or selling shares of Connect Biopharma?

James Huang has not been actively trading shares of Connect Biopharma over the course of the past ninety days. Most recently, on Friday, May 29th, James Huang bought 150,000 shares of Connect Biopharma stock. The stock was acquired at an average cost of $2.48 per share, with a total value of $372,000.00. Following the completion of the transaction, the director now directly owns 13,310,000 shares of the company's stock, valued at $33,008,800. Learn More on James Huang's trading history.

Are insiders buying or selling shares of Connect Biopharma?

During the last twelve months, Connect Biopharma insiders bought shares 2 times. They purchased a total of 1,310,000 shares worth more than $4,374,000.00. The most recent insider tranaction occured on May, 29th when Director James Huang bought 150,000 shares worth more than $372,000.00. Insiders at Connect Biopharma own 22.6% of the company. Learn More about insider trades at Connect Biopharma.

Information on this page was last updated on 5/29/2026.

James Huang Insider Trading History at Connect Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/29/2026Buy150,000$2.48$372,000.0013,310,000View SEC Filing Icon  
3/31/2026Buy1,160,000$3.45$4,002,000.0013,160,000View SEC Filing Icon  
See Full Table

James Huang Buying and Selling Activity at Connect Biopharma

This chart shows James Huang's buying and selling at Connect Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Connect Biopharma Company Overview

Connect Biopharma logo
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $2.33
Low: $2.33
High: $2.50

50 Day Range

MA: $2.26
Low: $1.97
High: $2.66

2 Week Range

Now: $2.33
Low: $1.23
High: $3.82

Volume

395,383 shs

Average Volume

295,934 shs

Market Capitalization

$146.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A